Emerging evidence demonstrates that ABX-1431, a novel MGLL inhibitor, effectively reverses progesterone resistance and enhances progesterone sensitivity in endometrial adenocarcinoma (34). The gene discussed is MGLL; the disease is endometrium adenocarcinoma.